Journal Article

Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies

Eugènia Negredo, Anna Bonjoch, Roger Paredes, Jordi Puig and Bonaventura Clotet

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 41, issue 6, pages 901-905
Published in print September 2005 | ISSN: 1058-4838
Published online September 2005 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/432879
Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.

Journal Article.  2382 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.